אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - meropenem trihydrate -

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - meropenem trihydrate, quantity: 570 mg (equivalent: meropenem, qty 500 mg) - injection, powder for - excipient ingredients: sodium carbonate - meropenem ranbaxy is indicated for the treatment of the following infections, in adults and children (aged 3 months and over), when the causative organisms are known or suspected to be resistant to commonly used antibiotics: - community acquired lower respiratory tract infection, - hospital acquired lower respiratory tract infection, - complicated urinary tract infection, - febrile neutropenia, - intra-abdominal and gynaecological (polymicrobial) infections, - complicated skin and skin structure infections, - meningitis, - septicaemia.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - meropenem trihydrate, quantity: 1140 mg (equivalent: meropenem, qty 1 g) - injection, powder for - excipient ingredients: sodium carbonate - meropenem ranbaxy is indicated for the treatment of the following infections, in adults and children (aged 3 months and over), when the causative organisms are known or suspected to be resistant to commonly used antibiotics: - community acquired lower respiratory tract infection, - hospital acquired lower respiratory tract infection, - complicated urinary tract infection, - febrile neutropenia, - intra-abdominal and gynaecological (polymicrobial) infections,- complicated skin and skin structure infections, - meningitis, - septicaemia.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - amoxicillin trihydrate,potassium clavulanate -

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - morphine hydrochloride trihydrate, quantity: 10 mg/ml - oral liquid, solution - excipient ingredients: citric acid; water for injections; sodium methyl hydroxybenzoate; disodium edetate; glycerol; sodium citrate dihydrate - ordine oral solution is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - morphine hydrochloride trihydrate, quantity: 5 mg/ml - oral liquid, solution - excipient ingredients: sodium citrate dihydrate; citric acid; sodium methyl hydroxybenzoate; glycerol; water for injections; disodium edetate - ordine oral solution is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - morphine hydrochloride trihydrate, quantity: 2 mg/ml - oral liquid, solution - excipient ingredients: sodium methyl hydroxybenzoate; glycerol; sodium citrate dihydrate; water for injections; disodium edetate; citric acid - ordine oral solution is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - morphine hydrochloride trihydrate, quantity: 1 mg/ml - oral liquid, solution - excipient ingredients: disodium edetate; glycerol; water for injections; sodium methyl hydroxybenzoate; citric acid; sodium citrate dihydrate - ordine oral solution is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - potassium clavulanate, quantity: 13.58 mg/ml (equivalent: clavulanic acid, qty 11.4 mg/ml); amoxicillin trihydrate, quantity: 91.84 mg/ml (equivalent: amoxicillin, qty 80 mg/ml) - suspension, powder for - excipient ingredients: citric acid; guar gum; sodium citrate; purified talc; aspartame; silicon dioxide; flavour - short-term treatment of the following bacterial infections when caused by sensitive organisms: skin and skin structure infections; urinary tract infections (complicated and uncomplicated); upper respiratory tract infections including sinusitis and otitis media; lower respiratory tract infections including acute exacerbations of chronic bronchitis and community acquired pneumonia. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to curam duo 400/57. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in microbiology, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to curam duo 400/57 should not require the addition of another antibiotic due to the amoxycillin content of curam duo 400/57.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amoxicillin trihydrate, quantity: 57.8 mg/ml (equivalent: amoxicillin, qty 50 mg/ml) - suspension, powder for - excipient ingredients: saccharin sodium; colloidal anhydrous silica; xanthan gum; sodium citrate dihydrate; sunset yellow fcf; sorbitol; flavour - indications: it is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms. note. therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e. coli (see section 5.1 pharmacodynamic properties - microbiology). respiratory (acute and chronic): h. influenzae; streptococcus; strep. pneumoniae; staphylococcus, nonpenicillinase producing; e. coli (see section 5.1 pharmacodynamic properties - microbiology). genitourinary tract (complicated and uncomplicated, acute and chronic): e. coli (see section 5.1 pharmacodynamic properties - microbiology), p. mirabilis and strep. faecalis. gonorrhoea: n. gonorrhoeae (nonpenicillinase producing). prophylaxis of endocarditis: amoxycillin may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis.